This is a preview of subscription content, log in via an institution to check access.
Notes
The cost-effectiveness modelling for the study was funded by Merck & Co., Inc.
Reference
Lundberg J, et al. Economic Evaluation of Posaconazole Versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infection in High-Risk Neutropenic Patients in Sweden. Clinical Drug Investigation : 13 May 2014. Available from: URL: http://doi.org/10.1007/s40261-014-0199-9
Rights and permissions
About this article
Cite this article
Posaconazole for IFI prevention: better outcomes, lower cost. PharmacoEcon Outcomes News 703, 7 (2014). https://doi.org/10.1007/s40274-014-1264-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1264-6